Yahoo! Finance
Tech Startup Puraclenz™ Launches Powerful Next-Gen Air Purifiers Proven To Proactively Destroy Viruses Mid-Air With Patented "Ozone Free" Ionization Technology
Get rewarded for investing more into Puraclenz:
Puraclenz Holdings, Inc. is the parent corporation of Puraclenz LLC, which is a wholly-owned subsidiary. Puraclenz LLC is the operating entity that was formed on June 25, 2020. The Company later formed Puraclenz Holdings, Inc. on December 29, 2021. All investors in this Reg CF offering will become shareholders of Puraclenz Holdings, Inc., which will be the sole member of Puraclenz LLC. The funds raised from this Reg CF offering and received by Puraclenz Holdings, Inc. will flow to Puraclenz LLC on an as-needed basis.
OVERVIEW
An air purifier redefining the standard of “clean air”
We’re not just another air purifier. Standard air cleaners only trap pathogens that pass through their filter… But us? We clean indoor air and surfaces at the source – destroying viruses, mold and bacteria - what we believe is the premier practice to clean air in today’s world.
With a Puraclenz device, you’re treated like one of NASA’s esteemed astronauts. We use an evolved form of the same technology (photocatalytic oxidation) used to provide clean air to astronauts on the International Space Station. Our products clean the air you breathe using IP-protected innovations.
The last two years of the ongoing global health crisis have created a new need. People are seeking a cost-effective and automatic solution to destroy pathogens mid-air and on surfaces.
It’s not enough to wear masks and wipe down surfaces anymore. Consumers need a product that raises the bar in technology, design, and price.
Model P1500 shown
the problem
We live in a world where pathogens dangerously disrupt every aspect of life. COVID-19 did and (continues to do) more damage than just getting people sick. Businesses closed. Graduations were canceled. Celebrations ruined. In the U.S. alone, there have been over 60 million Covid cases and over 829,000 Covid related deaths.
All types of pathogens, like viruses, bacteria, and mold, can cause major worldwide health issues. They are responsible for serious illnesses and infections, and even allergic reactions. Every year, 2.8 million bacterial infections occur in the U.S., and more than 35,000 people die. Up to 11% of people in the U.S. get the influenza flu annually. Even 93% of chronic sinus infections are attributed to mold. Excessive concentrations of bacteria, viruses, and molds can trigger asthma episodes for 15 million Americans.
People spend nearly 90% of their time indoors, and indoor air pollution is a top concern of the EPA. Typical indoor air contains two to five times more pollutants than outdoor air.
Standard air purifiers clearly aren’t effective enough at destroying these pathogens. HEPA, a standard device, only collects particles that pass through its filter. Then, it uses air changes to clean pathogens in the room.
These air changes take time. Ten to sixty minutes to be exact. By the time the cleaning is finished, people in the space could have already inhaled the pathogens.
the market
Puraclenz is addressing the fast-growing $11.6 billion air purification market. It’s estimated to accelerate to $22.8 billion over the next six years, with a 10% CAGR.
Source: Grand View Research
Industry analysts created those market estimates before COVID-19 started. We can only imagine the elevated market potential since the virus took off and developed its growing number of dangerous variants.
Several companies and technologies compete with us in the Interior Air Quality (IAQ) sector. This sector uses various technologies, including UV light-based systems, hydrogen peroxide, negative ionizers, and more.
Most competitors’ products are considered “passive” devices, which have serious drawbacks:
Only treat air that passes through their device
Less energy-efficient
Regularly require expensive filters changes
Do not clean surfaces
There is a large price range for air purification. UV robots can cost $125,000 and small HEPA products cost $99.99. Our tech exceeds both competing capabilities at a price range between $299 and $499.
Our proprietary technology offers a unique market opportunity for powerful, low-cost, and certified safe air. We believe Puraclenz is the lowest cost professional-grade system.
The company’s patent portfolio protects the advanced PCO design. We have four issued patents and six other pending patents. Plus our mass production process uses trade secrets that allow our purifiers to produce an extraordinarily high density of ions providing an unprecedented competitive advantage in the marketplace.
the solution
Complete air purification through small, inexpensive devices
Puraclenz provides continuous cleaning coverage in large areas with low energy consumption. And it’s easy too. Just plug in the unit, run continuously, and breathe easy knowing any pathogens are being destroyed at the source.
We believe Puraclenz is the next generation of indoor air purification. Our devices use internal UV light that reflects onto a patented titanium catalyst, generating an extraordinarily high density of positive and negatively charged ions. These ions are the heroes–– they cling to and deactivate the pathogens mid-air and on exposed surfaces.
We now sell three purifier models that clean 750, 1,500, or 3,000 square feet areas. Since Puraclenz generates no fumes or harmful chemicals and is certified ozone-free, it’s safe to use around children and pets. Our lab studies also show, when Puraclenz is used in a room, it overwhelmingly halts the growth of mold.
Puraclenz develops, manufactures, and markets its proprietary air purification products to businesses and consumers worldwide. In the U.S., we manage all marketing, sales, and customer support activities directly. We currently sell through three distribution channels.
PCO technology has been safely purifying the air and exposed surfaces for over 40 years. We advanced the power and safety of this technology with our patented cell design. Puraclenz’s design generates an extraordinarily high density of pathogen-destroying ions without producing any harmful by-products. Hand-cleaning or HEPA filters don’t cut it. Our design kills the pollutants they miss.
Why invest
Our numbers speak for themselves. Since we launched in May 2021, Puraclenz has already generated over $700,000 in revenue with thousands of installations. Many universities, luxury hotels, schools, fitness centers, grocery stores, and small businesses nationwide are using Puraclenz to clean their air and surfaces.
*Revenue of the company's subsidiary, Puraclenz, LLC.
We currently sell five SKUs through four distribution channels in the U.S., Canada, and Mexico. In the U.S., Puraclenz sells air purification equipment direct to home, business customers from Puraclenz.com, and in bulk through its team of sales reps and network of distributors. We have master distributor agreements for Canada and Mexico.
Puraclenz has an aggressive five-year growth plan to address this accelerating market. We hope to see annual revenues of $200 million at the end.
In 2022, Puraclenz plans to introduce four more SKUs and expand worldwide distribution to Europe, Japan, India, Southeast Asia, and the Middle East.
We project that U.S. distribution will also expand in the next two years. In 2022, Puraclenz hopes to expand distribution to online marketplaces like Amazon, Walmart.com, Rakuten, and Houzz. In 2023 and 2024, we aim that our products will be sold in home retail stores, such as Best Buy, Target, Bed Bath Beyond, Home Depot, Lowes, and more.
Global concerns of viral spread are growing. Every business and household needs better air purification. Our devices are scientifically proven to proactively reduce viruses mid-air and on exposed surfaces.
We believe Puraclenz’s geographic, application, and technology segmentation offers a large growth potential in the air purification market. Our products are backed by a strong and experienced management team and protected by a global patent portfolio.
This is your chance to participate in a market opportunity with disruptive technology. We’ve created a low-cost product that efficiently addresses what we feel is the biggest global health crisis in over 100 years. It feels good knowing we’re making a difference.
We’re so proud of our success with Puraclenz in just one year. Your investment will push us closer to our ambitious expansion goals in the years to come. Let’s protect people from pathogens and help them breathe easily. Join us!
Tech Startup Puraclenz™ Launches Powerful Next-Gen Air Purifiers Proven To Proactively Destroy Viruses Mid-Air With Patented "Ozone Free" Ionization Technology
The Puraclenz Air Purifier is Effective Against Bacteria
Tech Startup Puraclenz™ Launches Powerful Next-Gen Air Purifiers Proven To Proactively Destroy Viruses Mid-Air With Patented “Ozone Free” Ionization Technology
Breathe Easy With These Air Purifiers
Company | : | Puraclenz Holdings, Inc. |
Corporate Address | : | P.O. Box 733, Old Greenwich, CT 06870 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $1,070,000.00 |
Minimum Investment Amount(per investor) | : | $248.00 |
Offering Type | : | Equity |
Security Name | : | Class E Common Stock |
Minimum Number of Shares Offered | : | 1,250 |
Maximum Number of Shares Offered | : | 133,750 |
Price per Share | : | $8.00 |
Pre-Money Valuation | : | $29,698,766.62 |
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives and Bonuses*
Early Bird
Friends and Family: Invest within the first 72 hours and receive 15% bonus shares.
Super Early Bird: Invest within the first week and receive 10% bonus shares.
Early Bird Bonus: Invest within the first 2 weeks and receive 5% bonus shares.
Volume
Invest $500+: Receive 30% off first purchase (up to $150 retail value)
Invest $1,000+: Receive 1 FREE P750 Purifier ($299 retail value)
Invest $5,000+: Receive 5% bonus shares + Receive 2 FREE Purifiers of your choice (up to $999 retail value)
Invest $10,000+: Receive 7% bonus shares + Receive 3 FREE Purifiers of your choice (up to $1,499 retail value)
Invest $25,000+: Receive 10% bonus shares + Receive 4 FREE Purifiers of your choice (up to $1,999 retail value)
Invest $50,000+: Receive 15% bonus shares + Receive 6 FREE Purifiers of your choice (up to $2,999 retail value)
Invest $100,000+: Receive 20% bonus shares + Receive 8 FREE Purifiers of your choice (up to $4,999 retail value)
*All perks occur when offering is complete.
The 10% StartEngine Owners' Bonus
Puraclenz Holdings, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $8.00 / share, you will receive 10 additional shares of Class B Non-Voting Common Stock, meaning you'll own 110 shares for $800. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Insider Investment Notice
Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Puraclenz is pleased to announce that the United States Patent and Trademark Office
has granted a registered trademark for PURACLENZ
Get info on investing in Puraclenz: www.startengine.com/puraclenz
This important trademark joins the growing intellectual property portfolio owned by Puraclenz summarized below:
Canada Sales are Scaling Up. Puraclenz’s Canadian master distributor Ogena Solutions has issued a new $87,998 purchase order and also provided a forecast to purchase an additional $280,000 in 2022. Sales in Canada began in January 2022 and Ogena Solutions has made great distribution progress in just several months.
Ogena Solutions. In 2021, Puraclenz entered into an exclusive master distribution agreement with Ogena Solutions to sell our commercial line of products in Canada and to USA Animal Health customers. Ogena Solutions has forged an identity as one of the most respected animal health biosecurity companies in North America and over the last several years has been expanding its knowledge and experience into the human health sector. Following a ‘One Health’ philosophy, Ogena Solutions offers innovative, state-of-the-art products and technologies that meet the highest standards for efficacy, efficiency, and safety, providing best-in-class solutions for government agencies, corporations, and small businesses throughout the continent.
Get info on investing in Puraclenz: www.startengine.com/puraclenz
Puraclenz has an investment update. Insiders made investments in the amount of $10,496 in the Company’s current Reg CF offering. Please refer to the offering materials for further information and refer to the Company’s Risk Factors.
As part of the Company’s major effort to reduce its cost of goods sold and maintain our lowest professional grade pricing model, Puraclenz is moving mass production of its P-series products to Vietnam.
This will reduce Puraclenz's manufacturing costs by 25% for every P-series product imported into the USA by eliminating the Section 301 tariff and leveraging lower labor costs in Vietnam. Our CEO Chris Dooley has worked with the owners of our new manufacturer for over 20 years. They are a seasoned and trusted supplier to many Fortune 500 companies. The new Manufacturing Agreement was signed on March 25, 2022 and mass production in Vietnam will start before the end of 2022.
Get info on investing in Puraclenz: www.startengine.com/puraclenz
Puraclenz continues its strong revenue growth. Puraclenz's cumulative booked revenue is now over $885,000 including purchase orders received. The Company currently sells 5 SKU's through 4 channels of distribution in the USA, Canada and Mexico. In the USA, Puraclenz sells air purification equipment direct to home and business customers from Puraclenz.com, and in bulk through its team of sales reps and network of distributors.
Puraclenz’s network of authorized distributors is expanding. In the past month, Puraclenz has signed distribution agreements with 3 new distributors in California, North Carolina and Florida who are selling our products to their commercial clients including health care practitioners, municipal government agencies, non-profit organizations, and office space.
Get info on investing in Puraclenz: www.startengine.com/puraclenz
Our entire team is grateful for the tremendous support to all who have invested in our company thus far! There has been incredible momentum behind the campaign and at the moment of this message we have raised over $100k in investments in just over 1 week!
We will be posting updates here at least once per week to keep you apprised of all of the exciting new developments. You can also join the mailing list on our website and stay in touch on Facebook and Instagram.
New laboratory test results are in! A laboratory report will be issued showing how Puraclenz technology outperforms ordinary HEPA competitors.
World renown laboratory Eurofins in France conducted a surface test following EN 17272 standards that show a Puraclenz P3000 unit reduced Staphylococcus aureus bacteria by 95% inside a large 34.5 cubic meter test chamber. Staphylococcus aureus is an FDA recognized surrogate for MRSA, Strep Pnuemoniae and Strep Pyogenes that cause deadly infections. Plates with the live bacteria were placed over 10 feet away from the P3000 device during this test and the Puraclenz unit remotely reduced the pathogen by 95% over an 8 hour period. Ordinary air purifiers cannot destroy pathogens on surfaces like Puraclenz.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}